FHIR © HL7.org  |  Server Home  |  XIG Home  |  Server Source  |  FHIR  

FHIR IG Statistics: FHIR Resources

Resources - All Kinds, Realm US

18,284 resources

Type: Text:

By Version

By Authority

 

Start Prev Rows 10200 - 10400 Next

PackageVersionIdentityName/TitleStatusFMMWGDateAuth
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.336Breast Cancer N Stageactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.337Metastatic Sites All Breast SNOMEDCTactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.338Metastatic Sites All Breast ICD9active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.339Metastatic Sites All Breast ICD10active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.340Metastatic Sites All Breast (grouped, SNOMEDCT/ICD9/ICD10)active2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.341Aromatase_Inhibitor therapyactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.342Capivasertib_therapyactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.343Fulvestrant_therapyactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.344PTEN_geneactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.345PTEN_geneinterpretationactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.346PIK3CA_geneactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.347PI3KCA_geneinterpretationactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.348AKTI_geneactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.349AKTI_geneinterpretationactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.350Progesterone_receptor_geneactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.351Progesterone_receptor_geneinterpretationactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.352Estrogen_receptor_geneactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.353Estrogen_receptor_geneinterpretationactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.354Progesterone_receptor_labtestactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.355Progesterone_receptor_labinterpretationactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.356Estrogen_receptor_labtestactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.357Estrogen_receptor_labinterpretationactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.358NSCLC M0 Stageactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.359HER2_IHC_test_Geneactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.360HER2_IHC_test_Labactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.361HER2_Fish_testactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.362HER2_IHC_Negativeactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.363Trodelvyactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.364Chemotherapy_breast_canceractive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.365Cyclin_dependent_kinaseactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.366Taxane_Trodelvyactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.367Endocrine_therapyactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.368HER2_Fish_test_Negativeactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.369HER2_IHC_Equivocalactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.370HER2 Positive_PM_resultsactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.371HER2 test_Labactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.372HER2 test_geneactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.374Thyroid Cancer Diagnosisactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.375Metastatic_Thyroid_Stage Groupactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.376RET mutation_Molecular Variantsactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.377RET Gene mutationactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.378Locally_Advanced_Localized_Thyroid_Cancer_Stage Groupactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.379Thyroid cancer M1_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.380Thyroid_cancer_M0_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.381Thyroid_cancer_T_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.382Thyroid_cancer_T1_T2_T3_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.383Thyroid_cancer_T4_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.384Thyroid_cancer_N1b_Stage&Aboveactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.385Thyroid_cancer_N_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.386Medullary_thyroid_histologyactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.387RET test_Thyroid_cancer (HGNC)active2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.388RET Positiveactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.389NSCLC N3 Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.390CRC Cancer Diagnosis ICD9active2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.391CRC Cancer Diagnosis ICD10active2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.392CRC Cancer Diagnosis ICD9/ICD10active2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.393Metastatic_CRC_Cancer_Stage Groupactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.394Locally_Advanced_Localized_CRC_Stage Groupactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.395CRC cancer M Stage (metastatic)active2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.396CRC Cancer T Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.397CRC Cancer N Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.398KRAS_geneactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.399KRAS_negativeactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.40Locoregional Breast Canceractive2023-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.400Fluoropyrimidine_CRCactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.401Oxaliplatinactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.402Irinotecan_based_therapyactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.403anti_VEGF_therapy_CRCactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.404anti_EGFR_therapy_CRCactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.405fruquitinibactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.406Locally_Advanced_CRC_Stage Groupactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.407Localized_CRC_Stage Groupactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.408CRC cancer M0_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.409CRC_Cancer_T1_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.410CRC_Cancer_T2_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.411CRC_Cancer_T3_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.412CRC_Cancer_T4_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.413CRC Cancer N1 Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.414CRC Cancer N2 Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.415CRC Cancer N2b Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.416KRAS_G12C_MVactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.417KRAS_G12C_PMactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.418KRAS_positiveactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.419Adagrasibactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.42Breast Canceractive2023-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.420cetuximab_therapyactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.421Tamoxifen_therapyactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.423Endometrial Cancer Diagnosis ICD 10active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.425Endometrial Cancer Diagnosis ICD9CMactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.426Endometrial Cancer Diagnosisactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.428Localized_Endometerial_Stage Group SNOMEDactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.429Localized_Endometerial_Stage Group NCIMactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.431Endometrial_Sarcoma_Tumor_Histology_excactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.432Endometrial cancer M Stage (metastatic)active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.433Endometrial_M0_Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.436Prior_therapy_Endometrialactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.437Paclitaxel_therapyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.441Carboplatin_therapyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.442Durvalumab_therapyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.444MMR_Gene_Lab_LOINCactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.447MMR_Gene_HGNCactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.449Endometrial_ Cancer N Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.451Endometrial_N0_Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.453Endometrial_N1_N2_Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.455Endometrial_T1_T3_Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.456Endometrial_T3_Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.458Endometrial_T4_Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.459Endometrial Cancer T Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.46Endometrial Cancer ICD10active2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.460Localized_Endometerial_Stage Group_SNOMED/NCIMactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.461Metastatic Sites All CRCactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.462Metastatic Sites All CRC ICD 10active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.463Metastatic Sites All CRC ICD 9active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.464Metastatic Sites All CRC (grouped, SNOMEDCT/ICD9/ICD10)active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.465NTRK Repotrectinib Molecular Variantsactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.466NTRK_Gene_rearrangmentactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.467Prior_Systemic_therapy_Repotrectinibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.468NTRK_Positiveactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.469NTRK_test_geneactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.47Systemic treatment for endometrial canceractive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.470Tamoxifen_Trodelvyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.471Toremifene_trodelvyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.472Fulvestrant_Trodelvyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.473Elacestrantactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.474Anastrozole_Trodelvyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.475Leuprolide_Trodelvyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.476Abemaciclibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.477Palbociclibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.478Ribociclibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.479Carboplatin_Trodelvyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.48Endometrial Cancersactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.480Cisplatin_Trodelvyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.481Cyclophosphamideactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.482Methotrexateactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.483Gemcitabineactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.484Capecitabineactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.485Eribulinactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.486Doxorubicinactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.487Vinorelbineactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.488Epirubicinactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.489Ixabepiloneactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.490Olaparibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.491Talazoparibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.492Entrectinibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.493larotrectinibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.494Alpelisibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.495Capivasertibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.496Pembrolizumabactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.497Dostarlimabactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.498Selpercatinibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.499Everolimusactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.500Trastuzumab_deruxtecanactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.501Test 23active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.502All Metastatic sites Endometrial SNOMEDactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.503All Metastatic sites Endometrial ICD9active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.504All Metastatic sites Endometrial ICD10active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.505All Metastatic sites Endometrialactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.506Create CRC_Cancer_T4a_Stageactive2024-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.507Create CRC_Cancer_T4b_Stageactive2024-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.508High Emetogenic Risk Chemotherapyactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.510InactiveFollowupactive2025-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.53MMR Gene Testingactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.54MSI Highactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.55MSI Highactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.6Orserduactive2023-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.61Stage IIB or lower and limitedactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.62Stage III or higheractive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.63Stage III or higheractive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.64Stage III or higheractive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.65Staging Unknownactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.66Staging Unknownactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.67Staging Unknownactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.68Jemperliactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.69Uterine Sarcomaactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.7Her2 Test For Orserduactive2023-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.70Tumor Histologyactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.71Platinum based therapyactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.72Prior Therapies for Tucatinibactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.73Tucatinibactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.74Colorectal Cancer ICD10active2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.75Colorectal Cancer ICD9active2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.76Colorectal Cancer ICD9 and ICD10active2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.78Advanced or Unresectable Colorectal Cancer Stagingactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.790 to IIIB Colorectal Cancer Stagingactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.80Colorectal Cancer M1 Stageactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.81RAS Genesactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.82RAS Gene Interpretation Negative LOINCactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.83RAS Gene Interpretation Negative SNOMEDactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.84RAS Gene Interpretation Negative NCMactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.85RAS Gene Negativeactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.86RAS Gene Interpretation Positive SNOMEDactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.87RAS Gene Interpretation Positive LOINCactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.88RAS Gene Positiveactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.89Her2 Testingactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.90Patient Reasonactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.91MSI High NCIactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.92MSI Low SNOMEDactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.93MSI Low LOINCactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.94MSI Low NCIactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.95MSI Lowactive2024-01hl7